In 2018, Johnson & Johnson set out to revolutionize the way blood clots are studied. Their goal was to investigate how various clot characteristics such as size, composition, and density could impact patient outcomes. Additionally, they wanted to determine how two of their medical devices performed in removing clots from stroke patients.
To achieve this, they conducted a groundbreaking study that involved enrolling 1,000 stroke patients at 36 clinical trial sites worldwide. The study, known as the Excellent Registry, analyzed actual blood clots that had been removed from stroke patients on a per-pass basis. Independent evaluators reviewed the data to ensure accuracy and objectivity.
The Excellent Registry is the largest acute ischemic stroke registry globally, highlighting Johnson & Johnson’s commitment to innovation in advancing stroke care. With alarming statistics showing that every 40 seconds someone in the United States has a stroke and every 3.5 minutes someone dies from one, it is crucial for companies like Johnson & Johnson to continue their dedication to improving stroke care outcomes.
For more information about Johnson & Johnson’s efforts in this area, visit their website here.